CD79A and diffuse large B-cell lymphoma: By World Health Organization (WHO) classification, plasmoblastic lymphoma (PBL) is considered to be a new subtype of diffuse large B cell lymphoma (DLBCL) with distinct blastic morphology, antigenic phenotyping data indicating plasmacytic differentiation (CD20−, CD45−, CD79a+, and VS38c+), and clinical presentation favoring extramedullary sites, particularly the oral cavity and the mucosa of the jaw [1].